CN105859804A - Eucommia ulmoides extract as well as preparation method and application thereof - Google Patents
Eucommia ulmoides extract as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN105859804A CN105859804A CN201610267548.1A CN201610267548A CN105859804A CN 105859804 A CN105859804 A CN 105859804A CN 201610267548 A CN201610267548 A CN 201610267548A CN 105859804 A CN105859804 A CN 105859804A
- Authority
- CN
- China
- Prior art keywords
- cortex eucommiae
- ethanol
- column volume
- preparation
- extracts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a eucommia ulmoides extract as well as a preparation method and application thereof, belonging to the technical field of traditional Chinese medicine. The eucommia ulmoides extract contains the following components in percentage by mass: 3.10-3.70% of cycloolivil-9-glucoside, 1.40-1.70% of cycloolivil-4'-glucoside and 9.50-10.50% of arctiin. The eucommia ulmoides extract is prepared by the steps of eucommia ulmoides grinding, extraction, concentration, centrifugation, standing and separation using macroporous adsorption resin. The eucommia ulmoides extract has a remarkable anti-inflammatory effect.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly belong to a kind of Cortex Eucommiae extract and its preparation method and application.
Background technology
The Cortex Eucommiae (Eucommia ulmoides Oliv.) is the dry bark of the Eucommiaceae plant Cortex Eucommiae, is China's tradition name
Your tonic Chinese medicine, for invigorating the liver and kidney, bone and muscle strengthening.Modern pharmacology research finds, the Cortex Eucommiae has several functions activity, such as: fall blood
Pressure effect, defying age, anticancer, antibacterial, analgesia, antiinflammatory, diuresis, calmness, to calm the nerves, antivirus action, enhancing body is non-specific to be exempted from
Epidemic disease power, and cellular immunization can be carried out the effects such as dual modulation, additionally nerve centre is also had certain effect etc..
The Cortex Eucommiae being shown in, the chemical composition that document is reported includes lignanoids, iridoids, Phenylpropanoid Glycosides class, flavonoid etc.
About 200 chemical compositions altogether.Lignanoids compounds is most study in chemical component of eucommia bark used, composition is the clearest and the most definite, structure is the most clear
A clear compounds, separated obtain is double tetrahydrofuran compounds mostly.Up to now, separate from the Cortex Eucommiae
Lignanoids compounds have 44, mostly be glycosides compound, its glycosyl is β-D-Glucose.Structure type mostly is bis-epoxy
Lignanoid (bisepoxylignans, i.e. double tetrahydrofuran class), such as pinoresinol diglucoside, Flos Caryophylli fat diglucoside
Deng, the most a small amount of monocycle oxygen lignanoid (monoepoxylignans), neolignan (neolignans), sesquilignan
And ring lignanoid (cyclolignans) etc. (sesqiulignans).Have no Cortex Eucommiae report in terms of inflammatory applications.
Summary of the invention
It is an object of the invention to for defect described above, it is provided that a kind of Cortex Eucommiae extract with notable anti-inflammatory activity.
It is a further object of the present invention to provide the preparation method and application of a kind of Cortex Eucommiae extract.
It is an object of the invention to be accomplished by.
A kind of Cortex Eucommiae extract, extracts with the Cortex Eucommiae for raw material and obtains, described Cortex Eucommiae extract Fructus Canarii albi resin on ring
Element 9-glucosides, ring olivil 4'-glucosides and arctiin, its mass percent should be 3.10～3.70%, 1.40 mutually
～1.70%, 9.50～10.50%.
The preparation method of a kind of Cortex Eucommiae extract, comprises the steps:
Take the Cortex Eucommiae to pulverize, successively with the 80-95% alcohol reflux 2 times of its 8-12 times of volume, each 2h, filtration；Medicinal residues add
The 60-80% alcohol reflux of 6-10 times of volume 1 time, extracts 2h, filters；Merge 3 eucommoil extracts, reclaim ethanol also
It is concentrated into containing 0.4-0.6g crude drug ml-1Runny plaste；Runny plaste stands 12h, centrifugal, takes supernatant；Supernatant is with 0.8-
1.2mlmin-1Speed by HPD 100 macroporous resin；Applied sample amount is less than 2.0g crude drug ml-1Resin, successively with 4-6 times
Column volume purified water, 6-10 times of column volume 10-30% ethanol elution, discard, then wash with 6-10 times of column volume 80-95% ethanol
De-, collect 80-95% ethanol elution part, eluent decompression and solvent recovery, 60 DEG C are dried.Pulverize, to obtain final product.
Preferably include following steps:
Take the Cortex Eucommiae to pulverize, successively with 90% alcohol reflux 2 times of its 10 times of volumes, each 2h, filtration；Medicinal residues add 8 times of bodies
70% alcohol reflux of accumulated amount 1 time, extracts 2h, filters；Merge 3 eucommoil extracts, reclaim ethanol and be concentrated into containing 0.5g
Crude drug ml-1Runny plaste；Runny plaste stands 12h, centrifugal, takes supernatant；Supernatant is with 1.0mlmin-1Speed by HPD 100
Macroporous resin；Applied sample amount is less than 2.0g crude drug ml-1Resin, successively by 5 times of column volume purified water, 8 times of column volume 20% ethanol
Eluting, discards, and then with 8 times of column volume 90% ethanol elutions, collects 90% ethanol elution part, eluent decompression and solvent recovery,
60 DEG C are dried.Pulverize, to obtain final product.
Above-mentioned Cortex Eucommiae extract can be applied in anti-inflammatory drug.
Compared with prior art the invention has the beneficial effects as follows: present invention firstly provides with ring olivil 9-sugar
Glycosides, ring olivil 4'-glucosides and arctiin are the Cortex Eucommiae extract of main active.The test of pesticide effectiveness shows, the Cortex Eucommiae
Extract has obvious anti-inflammatory activity.
Detailed description of the invention
The present invention will be further described by the following examples, but not thereby limiting the invention.
The preparation one of embodiment 1 Cortex Eucommiae extract.
Eucommia ulmoides 20kg pulverizes, the 95% ethanol 220L being separately added into, heating and refluxing extraction 2 times, each 2 hours, filter
Cross；Medicinal residues add 80% ethanol 200L reflux, extract, 1 time, extract 2h, filter；Merge 3 eucommoil extracts, reclaim ethanol and concentrate
To containing 0.6g crude drug ml-1Runny plaste；Runny plaste stands 12h, centrifugal, takes supernatant；Supernatant is with 1.2mlmin-1Speed pass through
HPD 100 macroporous resin；Applied sample amount is less than 2.0g crude drug ml-1Resin, successively by 6 times of column volume purified water, 10 times of column volumes
20% ethanol elution, discards, and then with 10 times of column volume 90% ethanol elutions, collects 90% ethanol elution part, and eluent reduces pressure back
Receiving solvent, 60 DEG C are dried.Pulverize, obtain Cortex Eucommiae extract 0.32kg.
Through HPLC method assay, Cortex Eucommiae extract medium ring olivil 9-glucosides, ring olivil 4'-glucosides and
The content of arctiin is respectively 3.24%, and 1.52%, 9.77%.
The preparation two of embodiment 2 Cortex Eucommiae extract.
Eucommia ulmoides 100kg, the 90% ethanol 1000L being separately added into, heating and refluxing extraction 2 times, each 2 hours, filter；
Medicinal residues add 70% ethanol 800L reflux, extract, 1 time, extract 2h, filter；Merge 3 eucommoil extracts, reclaim ethanol being concentrated into and contain
0.5g crude drug ml-1Runny plaste；Runny plaste stands 12h, centrifugal, takes supernatant；Supernatant is with 1.0mlmin-1Speed pass through HPD
100 macroporous resins；Applied sample amount is less than 2.0g crude drug ml-1Resin, successively by 5 times of column volume purified water, 8 times of column volume 20% second
Alcohol eluting, discards, and then with 8 times of column volume 90% ethanol elutions, collects 90% ethanol elution part, and eluent recovered under reduced pressure is molten
Agent, 60 DEG C are dried.Pulverize, obtain Cortex Eucommiae extract 1.44kg.
Through HPLC method assay, Cortex Eucommiae extract medium ring olivil 9-glucosides, ring olivil 4'-glucosides and
The content of arctiin is respectively 3.53%, and 1.68%, 10.36%.
The application in terms of antiinflammatory of embodiment 3 Cortex Eucommiae extract.
Take male mice in kunming 60, male and female half and half, be randomly divided into negative control group (the CMC-Na solution of 0.6%),
Positive controls (aspirin 100mgkg-1, celecoxib 5mgkg-1), Cortex Eucommiae extract high, medium and low dosage group (400mgkg-1、200mgkg-1、100mgkg-1) often organize 10.Gastric infusion every day 1 time respectively of each treated animal, successive administration 3d, last is administered
Uniformly being applied to two sides before and after left ear with dimethylbenzene 0.1ml after 30min, auris dextra compares.After causing inflammation, 20min is by sacrifice, edge
Two ears cut by auricle line, lay auricle with the rustless steel card punch of diameter 8mm respectively at same position, weigh, with left and right auricle
The difference of quality be swelling.
Auricle edema suppression ratio (%)=(blank group auricle swelling degree average administration group auricle swelling degree average)/blank group
Auricle swelling degree average × 100%
Mice auricle swelling degree experimental result t inspection statistics through between group is analyzed, and shows Cortex Eucommiae extract each dosage group and model group
Relatively having pole significant difference (P < 0.01), display Cortex Eucommiae extract each dosage group all has good antiinflammatory action.Mouse ear
Wide swelling test the results are shown in Table 1.
Table 1 mouse auricle swelling test result
Note: compare with negative control group, * P < 0.01.
Claims (4)
1. the preparation method of a Cortex Eucommiae extract, it is characterised in that: described Cortex Eucommiae extract containing ring olivil 9-glucosides,
Ring olivil 4'-glucosides and arctiin, mass percent should be mutually 3.10～3.70%, 1.40～1.70%,
9.50～10.50%.
2. the preparation method of a kind of Cortex Eucommiae extract described in claim 1, it is characterised in that: comprise the steps: to take the Cortex Eucommiae
Pulverize, successively with the 80-95% alcohol reflux 2 times of its 8-12 times of volume, each 2h, filtration；Medicinal residues add 6-10 times of volume
The 60-80% alcohol reflux of amount 1 time, extracts 2h, filters；Merge 3 eucommoil extracts, reclaim ethanol being concentrated into and contain
0.4-0.6g crude drug ml-1Runny plaste；Runny plaste stands 12h, centrifugal, takes supernatant；Supernatant is with 0.8-1.2ml min-1Speed
Degree is by HPD 100 macroporous resin；Applied sample amount is less than 2.0g crude drug ml-1Resin, successively with 4-6 times of column volume purified water, 6-
10 times of column volume 10-30% ethanol elutions, discard, and then with 6-10 times of column volume 80-95% ethanol elution, collect 80-95% ethanol
Elution fraction, eluent decompression and solvent recovery, 60 DEG C dry, pulverize, to obtain final product.
The preparation method of a kind of Cortex Eucommiae extract the most according to claim 2, it is characterised in that: comprise the steps: to take
The Cortex Eucommiae is pulverized, successively with 90% alcohol reflux 2 times of its 10 times of volumes, and each 2h, filtration；Medicinal residues add 8 times of volumes
70% alcohol reflux 1 time, extracts 2h, filters；Merge 3 eucommoil extracts, reclaim ethanol and be concentrated into containing 0.5g crude drug
ml-1Runny plaste；Runny plaste stands 12h, centrifugal, takes supernatant；Supernatant is with 1.0ml min-1Speed by HPD 100 macropore
Resin；Applied sample amount is less than 2.0g crude drug ml-1Resin, successively by 5 times of column volume purified water, 8 times of column volume 20% ethanol elutions,
Discard, then with 8 times of column volume 90% ethanol elutions, collect 90% ethanol elution part, eluent decompression and solvent recovery, do for 60 DEG C
Dry, pulverize, to obtain final product.
4. a kind of Cortex Eucommiae extract described in claim 1, it is characterised in that: it is applied to prepare in anti-inflammatory drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610267548.1A CN105859804A (en) | 2016-04-27 | 2016-04-27 | Eucommia ulmoides extract as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610267548.1A CN105859804A (en) | 2016-04-27 | 2016-04-27 | Eucommia ulmoides extract as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105859804A true CN105859804A (en) | 2016-08-17 |
Family
ID=56629223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610267548.1A Pending CN105859804A (en) | 2016-04-27 | 2016-04-27 | Eucommia ulmoides extract as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105859804A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110679688A (en) * | 2019-10-31 | 2020-01-14 | 青川县川申农特产开发有限公司 | Honey oolong tea beverage |
| CN113559142A (en) * | 2021-08-20 | 2021-10-29 | 江西普正制药股份有限公司 | Extraction method and application of eucommia lignans |
| CN113797215A (en) * | 2021-08-31 | 2021-12-17 | 江西普正制药股份有限公司 | Composition containing pinoresinol and cycloolivil 9-glucoside and preparation method and application thereof |
| CN113797214A (en) * | 2021-08-31 | 2021-12-17 | 江西普正制药股份有限公司 | Composition containing cycloolivil 4' -glucoside and preparation method and application thereof |
| CN115837026A (en) * | 2022-11-08 | 2023-03-24 | 暨南大学附属第一医院（广州华侨医院） | Composition and application thereof in preparing medicine with anti-hepatitis effect |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1536991A (en) * | 2001-07-27 | 2004-10-13 | ��ѧ�빤ҵ�о�ίԱ�� | (f)-cycloolivil as antioxidant obtained from stereospermum personatum |
| CN1879644A (en) * | 2005-06-13 | 2006-12-20 | 海口绿科南药研究开发有限公司 | Use of actiin in preparation of anti-inflammatory drug |
| CN102101876A (en) * | 2010-11-23 | 2011-06-22 | 苏州派腾生物医药科技有限公司 | Preparation method of arctiin |
| CN102262132A (en) * | 2011-04-27 | 2011-11-30 | 江西普正制药有限公司 | Method for detecting quality of Chinese medicine eucommia preparation |
| CN104287996A (en) * | 2013-07-15 | 2015-01-21 | 江西普正制药有限公司 | Eucommia shampoo and preparing method thereof |
| CN104523849A (en) * | 2014-11-28 | 2015-04-22 | 普正药业股份有限公司 | Pharmaceutical composition of eucommia ulmoides iridoids and application thereof |
-
2016
- 2016-04-27 CN CN201610267548.1A patent/CN105859804A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1536991A (en) * | 2001-07-27 | 2004-10-13 | ��ѧ�빤ҵ�о�ίԱ�� | (f)-cycloolivil as antioxidant obtained from stereospermum personatum |
| CN1879644A (en) * | 2005-06-13 | 2006-12-20 | 海口绿科南药研究开发有限公司 | Use of actiin in preparation of anti-inflammatory drug |
| CN102101876A (en) * | 2010-11-23 | 2011-06-22 | 苏州派腾生物医药科技有限公司 | Preparation method of arctiin |
| CN102262132A (en) * | 2011-04-27 | 2011-11-30 | 江西普正制药有限公司 | Method for detecting quality of Chinese medicine eucommia preparation |
| CN104287996A (en) * | 2013-07-15 | 2015-01-21 | 江西普正制药有限公司 | Eucommia shampoo and preparing method thereof |
| CN104523849A (en) * | 2014-11-28 | 2015-04-22 | 普正药业股份有限公司 | Pharmaceutical composition of eucommia ulmoides iridoids and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 杨芳，等: "杜仲叶化学成分的研究", 《中国中药杂志》 * |
| 潘亚磊，等: "杜仲活性成分的提取及分离纯化方法研究进展", 《化学与生物工程》 * |
| 董娟娥，等: "大孔吸附树脂一次性分离杜仲叶中杜仲总苷和杜仲黄酮的研究", 《农业工程学报》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110679688A (en) * | 2019-10-31 | 2020-01-14 | 青川县川申农特产开发有限公司 | Honey oolong tea beverage |
| CN113559142A (en) * | 2021-08-20 | 2021-10-29 | 江西普正制药股份有限公司 | Extraction method and application of eucommia lignans |
| CN113797215A (en) * | 2021-08-31 | 2021-12-17 | 江西普正制药股份有限公司 | Composition containing pinoresinol and cycloolivil 9-glucoside and preparation method and application thereof |
| CN113797214A (en) * | 2021-08-31 | 2021-12-17 | 江西普正制药股份有限公司 | Composition containing cycloolivil 4' -glucoside and preparation method and application thereof |
| CN113797215B (en) * | 2021-08-31 | 2023-11-24 | 江西普正制药股份有限公司 | Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof |
| CN113797214B (en) * | 2021-08-31 | 2023-11-24 | 江西普正制药股份有限公司 | Composition containing cyclo-olivil 4' -glycoside and preparation method and application thereof |
| CN115837026A (en) * | 2022-11-08 | 2023-03-24 | 暨南大学附属第一医院（广州华侨医院） | Composition and application thereof in preparing medicine with anti-hepatitis effect |
| CN115837026B (en) * | 2022-11-08 | 2024-01-26 | 暨南大学附属第一医院（广州华侨医院） | Composition and application thereof in preparation of medicines with anti-hepatitis effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105859804A (en) | Eucommia ulmoides extract as well as preparation method and application thereof | |
| Guo et al. | Preliminary characterizations, antioxidant and hepatoprotective activity of polysaccharide from Cistanche deserticola | |
| CN110893197B (en) | Panax notoginseng extract for treating gout and preparation method thereof | |
| CN1813900B (en) | Kadsura longipedunculata lignin extract and its preparing method and use | |
| CN112870236B (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
| CN102772500B (en) | Relingqing Polygonum capitatum Buch-Ham ex D.Don raw material extract with anti-inflammatory action | |
| CN100500196C (en) | Method for preparing paris polyphylla total saponin | |
| CN103169788B (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
| WO2017181303A1 (en) | Method for preparing active ingredients of eurycoma longifolia and use thereof | |
| CN107929337A (en) | A kind of preparation method and application of Panax stipuleanatus Tsai et Feng anti-inflammatory active component | |
| CN103705594A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN102805767B (en) | Heat stranguria removal granule raw material polygonum capitatum extract with anti-gonococcus effect | |
| CN106236795B (en) | A Chinese medicinal preparation with antibacterial effect and its preparation method | |
| CN102772497B (en) | Alcohol extraction effective part of medicinal material of Relinqing granules and preparation method thereof | |
| CN104971088A (en) | Tibetan artemisia capillaris extract and preparation method, drug composition and application thereof | |
| CN115089694B (en) | Glycyrrhiza protein extract and new application thereof | |
| CN102357124B (en) | Chinese medicine combination with effects of detumescence and inflammatory resistance and preparation method thereof | |
| CN103893283A (en) | Traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method and use | |
| TWI612967B (en) | A use of an extract of asplenium australasicum (j. sm.) hook. | |
| CN103006781B (en) | Compound Dai medicine extract with liver-protecting effect and preparation method thereof | |
| CN102145040A (en) | Technique for adsorbing and extracting effective part of folium orthosiphoni by employing macroporous resin | |
| CN100431566C (en) | Chinese medicine composition and its prepn process and application | |
| CN101496880A (en) | Chinese medicinal composition for protecting liver and preparation method thereof | |
| CN101214325B (en) | Method for preparing compound 'chenxiangwei'medicine and new use thereof | |
| CN107582747B (en) | Preparation method of Jinma Gantai preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160817 |
|
| RJ01 | Rejection of invention patent application after publication |